This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Vascular Surgery  • Randomized Controlled Trial  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Cardiovascular Intervention  • Revascularization  • Alert me on articles by topic

The MULTISTRATEGY Randomized Trial

Marco Valgimigli, MD, PhD; Gianluca Campo, MD; Gianfranco Percoco, MD; Leonardo Bolognese, MD; Corrado Vassanelli, MD; Salvatore Colangelo, MD; Nicoletta de Cesare, MD; Alfredo E. Rodriguez, MD, PhD; Maurizio Ferrario, MD; Raul Moreno, MD; Tommaso Piva, MD; Imad Sheiban, MD; Giampaolo Pasquetto, MD; Francesco Prati, MD, PhD; Marco S. Nazzaro, MD, PhD; Giovanni Parrinello, PhD; Roberto Ferrari, MD, PhD; for the Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators

JAMA. 2008;299(15):1788-1799. Published online March 30, 2008 (doi:10.1001/jama.299.15.joc80026).

Context  Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI). It is uncertain whether there may be similar benefits in replacing abciximab with high-dose bolus tirofiban. Similarly, the use of drug-eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries.

Objective  To evaluate the effect of high-dose bolus tirofiban and of sirolimus-eluting stents as compared with abciximab infusion and uncoated-stent implantation in patients with STEMI undergoing percutaneous coronary intervention.

Design, Setting, and Patients  An open-label, 2 x 2 factorial trial of 745 patients presenting with STEMI or new left bundle-branch block at 16 referral centers in Italy, Spain, and Argentina between October 2004 and April 2007.

Interventions  High-dose bolus tirofiban vs abciximab infusion and sirolimus-eluting stent vs uncoated stent implantation.

Main Outcome Measures  For drug comparison, at least 50% ST-segment elevation resolution at 90 minutes postintervention with a prespecified noninferiority margin of 9% difference (relative risk, 0.89); for stent comparison, the rate of major adverse cardiac events, defined as the composite of death from any cause, reinfarction, and clinically driven target-vessel revascularization within 8 months.

Results  ST-segment resolution occurred in 302 of 361 patients (83.6%) who had received abciximab infusion and 308 of 361 (85.3%) who had received tirofiban infusion (relative risk, 1.020; 97.5% confidence interval, 0.958-1.086; P < .001 for noninferiority). Ischemic and hemorrhagic outcomes were similar in the tirofiban and abciximab groups. At 8 months, major adverse cardiac events occurred in 54 patients (14.5%) with uncoated stents and 29 (7.8%) with sirolimus stents (P = .004), predominantly reflecting a reduction of revascularization rates (10.2% vs 3.2%). The incidence of stent thrombosis was similar in the 2 stent groups.

Conclusions  In patients with STEMI undergoing percutaneous coronary intervention, compared with abciximab, tirofiban therapy was associated with noninferior resolution of ST-segment elevation at 90 minutes following coronary intervention, whereas sirolimus-eluting stent implantation was associated with a significantly lower risk of major adverse cardiac events than uncoated stents within 8 months after intervention.

Trial Registration  clinicaltrials.gov Identifier: NCT00229515

Author Affiliations: Cardiovascular Institute, University of Ferrara, Ferrara, Italy (Drs Valgimigli, Campo, Percoco, and Ferrari); Cardiovascular Research Centre, Salvatore Maugeri Foundation, IRCCS, Gussago (Brescia), Italy (Drs Valgimigli and Ferrari); Cardiovascular Department of San Donato Hospital, Arezzo, Italy (Dr Bolognese); Department of Biomedical and Surgical Sciences, Cardiology Section, University of Verona, Verona, Italy (Dr Vassanelli); Cardiovascular Intervention Laboratory, San Giovanni Bosco Hospital, Turin, Italy (Dr Colangelo); Policlinico S. Marco, Zingonia (Bergamo), Italy (Dr de Cesare); Otamendi Hospital, Buenos Aires, Argentina (Dr Rodriguez); Istituto di Ricovero e Cura a Carattere Scientifico, Policlinico S. Matteo, Pavia, Italy (Dr Ferrario); La Paz University Hospital, Madrid, Spain (Dr Moreno); Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I–GM Lancisi, Ancona, Italy (Dr Piva); Interventional Cardiology, University of Turin, San Giovanni Battista Hospital, Turin, Italy (Dr Sheiban); Department of Cardiology, Civic Hospital, Mirano (Venice), Italy (Dr Pasquetto); Department of Cardiovascular Medicine, Catholic University of the Sacred Heart, Rome, Italy (Dr Prati); San Camillo Hospital, Rome (Dr Nazzaro); and Medical Statistics Unit, University of Brescia, Brescia (Dr Parrinello).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Are High-Dose Tirofiban and Drug-Eluting Stents Best for STEMI?
Journal Watch Cardiology 2008;2008:1-1.
FULL TEXT